Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Statistics
  • Help & Advice
University of Warwick

The Library

  • Login

The Northwick Park tragedy - protecting healthy volunteers in future first-in-man trials

Tools
- Tools
+ Tools

Dowsing, T. and Kendall, M. J. (2007) The Northwick Park tragedy - protecting healthy volunteers in future first-in-man trials. Journal of Clinical Pharmacy and Therapeutics, Vol.32 (No.3). pp. 203-207. ISSN 0269-4727

Full text not available from this repository.
Official URL: http://dx.doi.org/10.1111/j.1365-2710.2007.00808.x

Abstract

The development of potentially powerful drugs which may become effective in the treatment for disorders currently difficult to manage presents the pharmaceutical industry and the scientific community with a major challenge. Such drugs with novel modes of action and the capacity to modify the body's immune system could also be very toxic. The possibility became a tragic reality on March 13th 2006 when TGN1412 was given to six healthy volunteers at Northwick Park hospital. All six became seriously ill. Fortunately none died but some were left with serious residual defects. The British Secretary of State for Health set up an Expert Scientific Group to investigate this tragic event. The report had to make recommendations designed to prevent a recurrence whilst not unduly delaying or discouraging the development of new drugs designed to treat cancers and other serious disorders. They made 22 recommendations. The drug TGN1412 had been shown to be well tolerated by non-human primates. A recent report on non-human primates in research recommended their continued use in some forms of research, for example on brain disorders. However, they also recommended that non-human primates should be used sparingly and only when justified scientifically. Their treatment should be optimal and research on them should be restricted to selected centres of expertise. The tragedy at Northwick Park should encourage the Pharmaceutical Industry to rethink their use of non-human primates in drug toxicity testing and hopefully to reduce their use and treat them better.

Item Type: Journal Item
Subjects: R Medicine > RS Pharmacy and materia medica
Divisions: Faculty of Medicine > Warwick Medical School
Journal or Publication Title: Journal of Clinical Pharmacy and Therapeutics
Publisher: Wiley-Blackwell Publishing Ltd.
ISSN: 0269-4727
Date: June 2007
Volume: Vol.32
Number: No.3
Number of Pages: 5
Page Range: pp. 203-207
Identification Number: 10.1111/j.1365-2710.2007.00808.x
Status: Not Peer Reviewed
Publication Status: Published
Access rights to Published version: Restricted or Subscription Access
Description: Commentary
URI: http://wrap.warwick.ac.uk/id/eprint/31884

Data sourced from Thomson Reuters' Web of Knowledge

Request changes to a record

Actions (login required)

View Item View Item
twitter

Email us: publications@warwick.ac.uk
Contact Details
About Us